Literature DB >> 19589201

Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas.

Kaisorn L Chaichana1, Matthew J McGirt, Graeme F Woodworth, Ghazala Datoo, Rafael J Tamargo, John Weingart, Alessandro Olivi, Henry Brem, Alfredo Quinones-Hinojosa.   

Abstract

OBJECTIVE: Hyperglycemia has been shown to augment tumor growth in vitro. However, the effects of persistent hyperglycemia on survival, recurrence and malignant degeneration in patients undergoing surgery for low grade gliomas remain unknown.
METHODS: All patients who underwent a craniotomy for hemispheric low grade glioma (WHO grade II) from 1996 to 2006 at a single institution were retrospectively reviewed. Persistent hyperglycemia was defined as serum glucose >180 microg/dl occurring three or more times between 1 and 3 months post-operatively. The independent association of outpatient glucose levels and recorded clinical and treatment variables with overall survival, tumor recurrence and malignant degeneration was assessed via separate multivariate proportional-hazards regression analyses.
RESULTS: In this study, 182 patients (89 fibrillary astrocytomas, 82 oligodendrogliomas and 11 mixed gliomas) were available for analysis. Eighteen (10%) patients experienced persistent hyperglycemia. Patients experiencing persistent hyperglycemia were older (44 +/- 16 versus 34 +/- 15) and more frequently diabetic [3 (17%) versus 4 (2%)]. All other clinical and treatment variables were not significantly different between the two cohorts. After adjusting for inter-group differences including age and diabetes and variables associated with survival and recurrence, persistent hyperglycemia was independently associated with decreased survival (p=0.001), increased recurrence (p=0.0001) and increased malignant degeneration (p<0.0001). This remained true after excluding all patients with diabetes and those on continued steroid administration. Five-year overall survival, progression-free survival and malignancy-free survival for persistent hyperglycemia versus relatively euglycemic cohorts were 43% versus 84%, 16% versus 46% and 46% versus 77%, respectively. DISCUSSION: These findings may provide useful insight for increasing survival, decreasing tumor recurrence and decreasing malignant degeneration in patients undergoing surgery for low grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589201     DOI: 10.1179/174313209X431101

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  18 in total

1.  Prognostic Significance of Hyperglycemia in Patients with Brain Tumors: a Meta-Analysis.

Authors:  Hongwei Liu; Zhixiong Liu; Bing Jiang; Xiping Ding; Lei Huo; Xin Wan; Jinfang Liu; Zhenyun Xia
Journal:  Mol Neurobiol       Date:  2015-02-17       Impact factor: 5.590

Review 2.  Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma.

Authors:  Angela Poff; Andrew P Koutnik; Kathleen M Egan; Solmaz Sahebjam; Dominic D'Agostino; Nagi B Kumar
Journal:  Semin Cancer Biol       Date:  2017-12-30       Impact factor: 15.707

3.  Postoperative mortality after surgery for brain tumors by patient insurance status in the United States.

Authors:  Eric N Momin; Hadie Adams; Russell T Shinohara; Constantine Frangakis; Henry Brem; Alfredo Quiñones-Hinojosa
Journal:  Arch Surg       Date:  2012-11

Review 4.  Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies.

Authors:  P D Delgado-López; E M Corrales-García; J Martino; E Lastra-Aras; M T Dueñas-Polo
Journal:  Clin Transl Oncol       Date:  2017-03-02       Impact factor: 3.405

5.  Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report.

Authors:  Giulio Zuccoli; Norina Marcello; Anna Pisanello; Franco Servadei; Salvatore Vaccaro; Purna Mukherjee; Thomas N Seyfried
Journal:  Nutr Metab (Lond)       Date:  2010-04-22       Impact factor: 4.169

6.  Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme.

Authors:  Rebecca B Little; Robert A Oster; Betty E Darnell; Wendy Demark-Wahnefried; L Burt Nabors
Journal:  Nutr Cancer       Date:  2016-06-24       Impact factor: 2.900

7.  Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients.

Authors:  Mary R Welch; Christian Grommes
Journal:  CNS Oncol       Date:  2013-05

8.  Prediagnostic body weight and survival in high grade glioma.

Authors:  Erin M Siegel; L Burton Nabors; Reid C Thompson; Jeffrey J Olson; James E Browning; Melissa H Madden; Gang Han; Kathleen M Egan
Journal:  J Neurooncol       Date:  2013-05-11       Impact factor: 4.130

Review 9.  The role of emerging therapy in the management of patients with diffuse low grade glioma.

Authors:  Andrew E Sloan; Hideho Okada; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

10.  Early incidence of glucocorticoid-induced diabetes in patients with brain tumors: a retrospective study of the first 7 days of treatment.

Authors:  Helga Schultz; Birthe Krogh Rasmussen; Peter Lommer Kristensen; Andreas Kryger Jensen; Ulrik Pedersen-Bjergaard
Journal:  Neurooncol Pract       Date:  2017-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.